Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels

We investigated whether serum hs-CRP levels predict the efficacy of atrial fibrillation (AF) treated with atorvastatin. Bibliographic databases were exhaustively searched for studies relevant to the research topic. Newcastle-Ottawa Scale (NOS) criteria, combined with the Quality Assessment of Diagno...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2015-01, Vol.2015 (2015), p.1-10
Main Authors: Gu, Hong-Yue, Yin, Feng, Jiang, Li, Teng, Shi-Chao, Xue, Feng-Hua, Shi, Ming-Yu, Sun, Shao-Xia, Li, Xi-Dong, Su, Fang-Cheng, Zhu, Jing
Format: Article
Language:English
Subjects:
Adult
Atorvastatin Calcium - therapeutic use
Atrial fibrillation
Atrial Fibrillation - blood
Atrial Fibrillation - drug therapy
C-reactive protein
C-Reactive Protein - metabolism
Case-Control Studies
Cholesterol
Drug therapy
Female
Health aspects
Heart attacks
Humans
Male
Methods
Middle Aged
Odds Ratio
Patient outcomes
Publication Bias
Statins
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated whether serum hs-CRP levels predict the efficacy of atrial fibrillation (AF) treated with atorvastatin. Bibliographic databases were exhaustively searched for studies relevant to the research topic. Newcastle-Ottawa Scale (NOS) criteria, combined with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS), were applied for study quality assessment. Our meta-analysis identified seven cohort studies (2006~2013), providing information on the change in serum hs-CRP levels in AF patients receiving atorvastatin therapy. After atorvastatin treatment, hs-CRP level in AF patients decreased significantly (SMD = 1.02, 95% CI: 0.58–1.47, P < 0.001 ). Subgroup analysis by country and hs-CRP detection methods suggested a negative relationship between atorvastatin treatment and hs-CRP levels among Chinese AF patients (SMD = 1.34, 95% CI: 1.00–1.69, P < 0.001 ) and by using ELISA method (SMD = 1.11, 95% CI: 0.51–1.71, P < 0.001 ), but not among Turkish population and using INA method (all P > 0.05 ). Egger’s test showed no publication bias ( P = 0.450 ). hs-CRP was clearly lowered in AF patients treated with atorvastatin, which may be helpful in the choice of statin agents for AF treatment. However, longer follow-ups are necessary to assess the clinical value of lowering hs-CRP in the clinical setting of AF treatment outcomes.
ISSN:2314-6133
2314-6141
DOI:10.1155/2015/402481